Equities analysts predict that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will post $114.08 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Biohaven Pharmaceutical’s earnings. The lowest sales estimate is $99.51 million and the highest is $124.35 million. Biohaven Pharmaceutical reported sales of $17.66 million during the same quarter last year, which indicates a positive year-over-year growth rate of 546%. The business is scheduled to issue its next earnings results on Monday, November 8th.
On average, analysts expect that Biohaven Pharmaceutical will report full year sales of $391.08 million for the current financial year, with estimates ranging from $357.34 million to $443.71 million. For the next fiscal year, analysts anticipate that the firm will report sales of $747.10 million, with estimates ranging from $664.56 million to $872.21 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Sunday, August 8th. The company reported ($3.23) EPS for the quarter, missing the consensus estimate of ($2.77) by ($0.46). The business had revenue of $92.93 million for the quarter, compared to analyst estimates of $85.85 million. During the same period last year, the firm posted ($2.55) EPS. The company’s revenue for the quarter was up 858.3% on a year-over-year basis.
A number of institutional investors have recently modified their holdings of BHVN. Harbor Investment Advisory LLC lifted its stake in Biohaven Pharmaceutical by 3,470.0% in the 2nd quarter. Harbor Investment Advisory LLC now owns 357 shares of the company’s stock valued at $35,000 after buying an additional 347 shares in the last quarter. Elkhorn Partners Limited Partnership purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $68,000. Lazard Asset Management LLC lifted its stake in Biohaven Pharmaceutical by 732.1% in the 2nd quarter. Lazard Asset Management LLC now owns 882 shares of the company’s stock valued at $85,000 after buying an additional 776 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $116,000. Finally, Harbour Investments Inc. purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $124,000. 92.14% of the stock is currently owned by hedge funds and other institutional investors.
NYSE BHVN traded up $0.63 on Friday, hitting $135.97. 6,704 shares of the company’s stock traded hands, compared to its average volume of 621,735. Biohaven Pharmaceutical has a 1-year low of $57.70 and a 1-year high of $139.50. The firm’s 50-day moving average price is $124.29 and its two-hundred day moving average price is $95.81. The firm has a market capitalization of $8.89 billion, a PE ratio of -9.44 and a beta of 1.03.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.
Recommended Story: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.